Bahar KURT,
Sibel ARINÇ,
Elif TANRIVERDİ,
Nuri TUTAR,
Ayşegül ŞENTÜRK,
Ayşe BAHADIR,
Murat KAVAS,
Füsun ŞAHİN,
Dilek ERGÜN,
Elif YILMAZEL UÇAR,
Talat KILIÇ,
İnci GÜLMEZ,
Jülide CELDİR EMRE,
Deniz DOĞAN,
Fatma ÖZDEMİR,
Mustafa DÜGER,
Suha ALZAFER,
Esra YARAR,
Damla Serce UNAT,
Bilge SALIK,
Nur Aleyna
11922
Frequency of Direct Oral Anticoagulants Usage in Acute Pulmonary Thromboembolism Treatment in Turkey (TUPEDO)
Frequency of Direct Oral Anticoagulants Usage in Acute Pulmonary Thromboembolism Treatment in Turkey (TUPEDO)
Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic range, and necessary close International Normalized Ratio (INR) monitoring. Phase 3 study results have reported that these drugs are at least as effective as warfarin and beneficial in terms of bleeding; however, studies that present up-to-date life data are necessary. Aims: To evaluate the frequency of using DOACs, which are prescribed with a limited number of indications in our country, and real-life data results. Study Design: Cross-sectional study Methods: This cross-sectional survey collected the clinical data (history, current treatment, treatment duration, etc.) of patients with pulmonary thromboembolism and who applied to the physician for follow-up between October 15, 2019, and March 15, 2020. The researchers kept the patient records sequentially. Results: Data from 836 patients with acute pulmonary thromboembolism from 25 centers were collected, and DOAC was used in 320 (38.5%) of them. The most preferred DOAC was rivaroxaban (n = 294, 91.9%). DOAC was mostly preferred because it could not provide an effective INR level with warfarin (n=133, 41.6%). Bleeding was observed in 13 (4%) patients. Conclusion: The use of direct oral anticoagulants is becoming almost as widespread as conventional therapy. Real-life data results are important for their contribution to clinical practice.
___
- 1. Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants What Clinicians Need to Know. Pharmacotherapy. 2017;37:236-248. [CrossRef]
- 2. Einstein Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010;363:2499-2510. [CrossRef]
- 3. Einstein-PE Investigators, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Engl J Med. 2012;366:1287- 1297. [CrossRef]
- 4. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808. [CrossRef]
- 5. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764-772. [CrossRef]
- 6. Hokusai VTE Investigators, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New Engl J Med. 2013;369:1406-1415. [CrossRef]
- 7. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New Engl J Med. 2009;361:2342-2352. [CrossRef]
- 8. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013;11:21. [CrossRef]
- 9. Konstantinides SV, Meyer G, Becattini C, et al. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54:1901647. [CrossRef]
- 10. (24.03.2013 Resmî Gazete Sayısı: 28597.) [CrossRef]
- 11. Eldredge JB, Spyropoulos AC. Direct oral anticoagulants in the treatment of pulmonary embolism. Curr Med Res Opin. 2018;34:131-140. [CrossRef]
- 12. Chopard R, Andarelli JN, Humbert S, et al. Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry. Thromb Res. 2019;174:27-33. [CrossRef]
- 13. Jara-Palomares L, Sanchez-Oro-Gomez R, Elias-Hernandez T, et al. Rivaroxaban for the treatment of venous thromboembolism. A ‘real-life’ perspective in 103 patients. Thromb Res. 2014;34:617-621. [CrossRef]
- 14. Imberti D, Barillari G; eXperience VTE Italian Group. Real-Life Management of Venous Thromboembolism With Rivaroxaban: Results From EXperience VTE, an Italian Epidemiological Survey. Clin Appl Thromb Hemost. 2018;24:241-247. [CrossRef]
- 15. Sayın B, Okutucu S, Yılmaz MB, et al. Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in TURKEY: inferences from GARFIELD-AF registry. Anatol J Cardiol. 2019;21:272-280. [CrossRef]
- 16. Başaran O, Beton O, Doğan V, et al. ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). Anatol J Cardiol. 2016;16:734-741. [CrossRef]
- 17. Altay S, Yıldırımtürk Ö, Çakmak HA, et al. New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. Anatol J Cardiol. 2017;17:353- 361. [CrossRef]